These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 20645912)
1. Using PET studies of P-gp function to elucidate mechanisms underlying the disposition of drugs. Syvänen S; Hammarlund-Udenaes M Curr Top Med Chem; 2010; 10(17):1799-809. PubMed ID: 20645912 [TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis of P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier in humans. Sugimoto H; Hirabayashi H; Amano N; Moriwaki T Drug Metab Dispos; 2013 Apr; 41(4):683-8. PubMed ID: 23340958 [TBL] [Abstract][Full Text] [Related]
3. Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates. Damont A; Goutal S; Auvity S; Valette H; Kuhnast B; Saba W; Tournier N Eur J Pharm Sci; 2016 Aug; 91():98-104. PubMed ID: 27283486 [TBL] [Abstract][Full Text] [Related]
4. 11C-verapamil to assess P-gp function in human brain during aging, depression and neurodegenerative disease. Bartels AL; de Klerk OL; Kortekaas R; de Vries JJ; Leenders KL Curr Top Med Chem; 2010; 10(17):1775-84. PubMed ID: 20645917 [TBL] [Abstract][Full Text] [Related]
5. Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography. Wanek T; Römermann K; Mairinger S; Stanek J; Sauberer M; Filip T; Traxl A; Kuntner C; Pahnke J; Bauer F; Erker T; Löscher W; Müller M; Langer O Mol Pharm; 2015 Sep; 12(9):3214-25. PubMed ID: 26202880 [TBL] [Abstract][Full Text] [Related]
6. N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier. Kannan P; Brimacombe KR; Zoghbi SS; Liow JS; Morse C; Taku AK; Pike VW; Halldin C; Innis RB; Gottesman MM; Hall MD Drug Metab Dispos; 2010 Jun; 38(6):917-22. PubMed ID: 20212014 [TBL] [Abstract][Full Text] [Related]
7. Human brain imaging and radiation dosimetry of 11C-N-desmethyl-loperamide, a PET radiotracer to measure the function of P-glycoprotein. Seneca N; Zoghbi SS; Liow JS; Kreisl W; Herscovitch P; Jenko K; Gladding RL; Taku A; Pike VW; Innis RB J Nucl Med; 2009 May; 50(5):807-13. PubMed ID: 19372478 [TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein function at the blood-brain barrier imaged using 11C-N-desmethyl-loperamide in monkeys. Liow JS; Kreisl W; Zoghbi SS; Lazarova N; Seneca N; Gladding RL; Taku A; Herscovitch P; Pike VW; Innis RB J Nucl Med; 2009 Jan; 50(1):108-15. PubMed ID: 19091890 [TBL] [Abstract][Full Text] [Related]
10. Successful Prediction of Human Steady-State Unbound Brain-to-Plasma Concentration Ratio of P-gp Substrates Using the Proteomics-Informed Relative Expression Factor Approach. Storelli F; Anoshchenko O; Unadkat JD Clin Pharmacol Ther; 2021 Aug; 110(2):432-442. PubMed ID: 33675056 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function. Lazarova N; Zoghbi SS; Hong J; Seneca N; Tuan E; Gladding RL; Liow JS; Taku A; Innis RB; Pike VW J Med Chem; 2008 Oct; 51(19):6034-43. PubMed ID: 18783208 [TBL] [Abstract][Full Text] [Related]
12. [PET imaging to study the functional impact of P-glycoprotein in neuropharmacokinetics]. Marie S; Tournier N Therapie; 2020; 75(6):623-632. PubMed ID: 32200996 [TBL] [Abstract][Full Text] [Related]
13. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET. Bankstahl JP; Kuntner C; Abrahim A; Karch R; Stanek J; Wanek T; Wadsak W; Kletter K; Müller M; Löscher W; Langer O J Nucl Med; 2008 Aug; 49(8):1328-35. PubMed ID: 18632828 [TBL] [Abstract][Full Text] [Related]
14. Influence of P-glycoprotein on pulmonary disposition of the model substrate [ Mairinger S; Hernández-Lozano I; Filip T; Löbsch M; Stanek J; Zeitlinger M; Hacker M; Tournier N; Wanek T; Ehrhardt C; Langer O Eur J Pharm Sci; 2023 Apr; 183():106404. PubMed ID: 36773747 [TBL] [Abstract][Full Text] [Related]
15. P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide. Kreisl WC; Liow JS; Kimura N; Seneca N; Zoghbi SS; Morse CL; Herscovitch P; Pike VW; Innis RB J Nucl Med; 2010 Apr; 51(4):559-66. PubMed ID: 20237038 [TBL] [Abstract][Full Text] [Related]
16. Modeling cyclosporine A inhibition of the distribution of a P-glycoprotein PET ligand, 11C-verapamil, into the maternal brain and fetal liver of the pregnant nonhuman primate: impact of tissue blood flow and site of inhibition. Ke AB; Eyal S; Chung FS; Link JM; Mankoff DA; Muzi M; Unadkat JD J Nucl Med; 2013 Mar; 54(3):437-46. PubMed ID: 23359659 [TBL] [Abstract][Full Text] [Related]
17. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET. Wagner CC; Bauer M; Karch R; Feurstein T; Kopp S; Chiba P; Kletter K; Löscher W; Müller M; Zeitlinger M; Langer O J Nucl Med; 2009 Dec; 50(12):1954-61. PubMed ID: 19910428 [TBL] [Abstract][Full Text] [Related]
18. A high-yield route to synthesize the P-glycoprotein radioligand [11C]N-desmethyl-loperamide and its parent radioligand [11C]loperamide. Wang M; Gao M; Zheng QH Bioorg Med Chem Lett; 2013 Oct; 23(19):5259-63. PubMed ID: 23981899 [TBL] [Abstract][Full Text] [Related]
19. Increased permeability-glycoprotein inhibition at the human blood-brain barrier can be safely achieved by performing PET during peak plasma concentrations of tariquidar. Kreisl WC; Bhatia R; Morse CL; Woock AE; Zoghbi SS; Shetty HU; Pike VW; Innis RB J Nucl Med; 2015 Jan; 56(1):82-7. PubMed ID: 25500831 [TBL] [Abstract][Full Text] [Related]
20. Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans. Muzi M; Mankoff DA; Link JM; Shoner S; Collier AC; Sasongko L; Unadkat JD J Nucl Med; 2009 Aug; 50(8):1267-75. PubMed ID: 19617341 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]